Evidence and Value-Based Purchasing for Value Analysis. Part 3 of 4.

vbp_1200.jpgWelcome back for part 3 of our 4-part series! We’re just past the halfway mark in our effort to tell you about the impact of evidence on value-based purchasing (VBP). If you found the previous installments informative, please share these blogs with your fellow supply chain and value analysis professionals. Don’t forget, you can also download our free eBook, Evidence: The 5th Domain of Value-Based Purchasing to read the content of this series in one complete package.

Need to catch up? Here’s part 2.

Let’s review our third VBP domain: Clinical Care (Outcomes and Process).

Clinical Care (Outcomes and Process)

outcomes_1200.jpgFor 2017, CMS’s performance metrics in this domain are tied to:

  • Fibrolyntic agents received within 30 minutes of hospital arrival following an ischemic stroke
  • Influenza immunizations
  • Elective delivery prior to 39 weeks gestation

 

“Creation of standardized care protocols based on thoroughly scrutinized, high-quality research studies can assist in significantly lowering mortality rates associated with serious conditions.”

Get the eBook

In addition, CMS’s performance metrics are linked to 30-day mortality rates for:

  • Acute myocardial infarction (AMI)
  • Heart failure
  • Pneumonia

These process and outcome metrics have been clearly supported by high-quality evidence as indicative of the quality and value of care within a given health system.

“Product standardization utilizing the best available evidence can ensure that the selection of a fibrolyntic agent is equivalent, if not superior, in safety and effectiveness to all available agents, that the same fibrolyntic agent is used each time, and that it was used in the manner in which it was intended. If all products are clinically equivalent, other considerations such as cost should drive the selection.”

Evidence Impact on Clinical Care

act on evidence_1200.jpgEvidence-based standardization is key. As in the CLABSI example in the second blog in this series, creation of standardized care protocols based on thoroughly scrutinized, high-quality research studies can assist in significantly lowering mortality rates associated with these conditions. In addition, product standardization utilizing the best available evidence can ensure that the selection of a fibrolyntic agent is equivalent, if not superior, in safety and effectiveness to all available agents, that the same fibrolyntic agent is used each time, and that it was used in the manner in which it was intended. If all products are clinically equivalent, other considerations such as cost should drive the selection.

Drugs chosen to manage acute myocardial infarct (AMI) should also be standardized within the context of an evidence-based clinical pathway. Failure to adhere to evidence-based guidelines have repeatedly been linked to higher morbidity and mortality rates. Confirming compliance with such guidelines, as reflected in adherence to applicable order-sets, would be one way to measure key process metrics shown to be linked to desirable outcomes.

Only one domain remains! Check in next week for the conclusion of our series, where we will also discuss how executive compensation is tied into VBP initiatives.

In the meantime, click the link below to download our new FREE eBook, Evidence: The 5th Domain of Value-Based Purchasing.

Get the eBook

Topics: Hospitals, Hayes Blog, Healthcare Evidence

Sign up to receive updates from our blog

Our latest articles

New Call-to-action